Holen Sie sich die Stockscreener-App
44.43
3.18%
1.31
Schlusskurs vom Vortag:
$43.12
Offen:
$43.67
24-Stunden-Volumen:
286.69K
Relative Volume:
0.68
Marktkapitalisierung:
$2.01B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.57M
KGV:
-23.18
EPS:
-1.9166
Netto-Cashflow:
$-72.14M
1W Leistung:
+1.14%
1M Leistung:
+25.79%
6M Leistung:
+2.97%
1J Leistung:
+112.27%
1-Tages-Spanne:
$43.00
$45.00
1-Wochen-Bereich:
$40.92
$45.00
52-Wochen-Spanne:
$16.38
$48.45
Sionna Therapeutics Inc Stock (SION) Company Profile
Firmenname
Sionna Therapeutics Inc
Sektor
Branche
Telefon
617-819-2020
Adresse
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
44.43 | 1.99B | 0 | -85.57M | -72.14M | -1.9166 |
VRTX
Vertex Pharmaceuticals Inc
|
524.31 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.45 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.25 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.81 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Citizens | Mkt Outperform |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-09-03 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-04 | Eingeleitet | Guggenheim | Buy |
| 2025-03-04 | Eingeleitet | Stifel | Buy |
| 2025-03-04 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Sionna Therapeutics Inc Aktie (SION) Neueste Nachrichten
ETFs Investing in Sionna Therapeutics, Inc. Stocks - TradingView
SIONSionna Therapeutics Inc Options - Finviz
Sionna Therapeutics director Thompson sells $5.27m in stock - Investing.com
Form 4 Sionna Therapeutics Inc For: 2 July By Investing.com - Investing.com UK
Sionna Therapeutics (SION) 10K Form and Latest SEC Filings 2026 - MarketBeat
Enterprise value to EBITDA forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Enterprise value to EBIT forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Enterprise value to revenue forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Price to earnings forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Price to sales forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment (SION) - Seeking Alpha
Sionna Therapeutics, Inc.(NasdaqGM: SION) dropped from Russell 3000E Index - marketscreener.com
Sionna Therapeutics, Inc.(NasdaqGM: SION) dropped from Russell Microcap Index - marketscreener.com
Sionna Therapeutics, Inc. Actuals & Estimates (NASDAQ:SION) - TradingView
SION Forecast — Price Target — Prediction for 2027 - TradingView
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Sionna Therapeutics, Inc. (SION) and Crescent Biopharma (CBIO) - The Globe and Mail
Citizens reiterates Sionna Therapeutics stock rating ahead of summer data By Investing.com - Investing.com Nigeria
Sionna Therapeutics: Buy Rating Reiterated on NBD1-Focused CF Strategy; $60 Price Target Maintained - TipRanks
Sionna Stockholders Reelect Directors, Ratify Deloitte as Auditor - The Globe and Mail
SION Q1 2026 Earnings: Wider Loss Surprises as Clinical Progress ContinuesFinal Results - newsline.com
Sionna Therapeutics - The Business Journals
Assessing Sionna Therapeutics (SION) Valuation After A Mixed Period For Recent Share Price Returns - Yahoo Finance
Transcript : Sionna Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10 - marketscreener.com
Sionna Therapeutics (SION) Gains 1.81% as Biotech Sentiment ImprovesBeta Neutral Pair - newsline.com
SION Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Faces Investor SkepticismGrowth Acceleration Report - newsline.com
Sionna Therapeutics (SION) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Biotech Sionna Therapeutics at Jefferies and Goldman Sachs in June - Stock Titan
Sionna Therapeutics director Peter Thompson sells $4,493 of shares - Investing.com India
Sionna Therapeutics director Peter Thompson sells $4,493 of shares By Investing.com - Investing.com South Africa
OrbiMed Advisors, director, sells $4,493 in Sionna Therapeutics stock - Investing.com
OrbiMed Advisors, director, sells $4,493 in Sionna Therapeutics stock By Investing.com - Investing.com UK
Form 144 | Sionna Therapeutics(SION.US) Insider Proposes to Sell 46.33 Million in Common Stocks - Moomoo
Sionna Therapeutics (SION) Sees Slight Decline Amidst Key Support TestPre-Earnings Momentum - The Legal Advocate
Sionna Therapeutics (SION) Edges Higher as Biotech Sentiment Improves — Testing Key ResistanceAdvance Decline Volume - thelegaladvocate.com
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences - markets.businessinsider.com
SION Reiterates by Citizens -- Price Target Maintained at $63 - GuruFocus
Stifel Nicolaus Sticks to Their Buy Rating for Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Stifel reiterates Buy on Sionna Therapeutics stock ahead of data - Investing.com
Stifel reiterates Buy on Sionna Therapeutics stock ahead of data By Investing.com - Investing.com Canada
Citizens reiterates Sionna Therapeutics stock rating on CF treatment potential By Investing.com - Investing.com Canada
SION Q1 2026 Earnings: Clinical-Stage Biotech Misses Estimates with Wider Net LossEarnings Growth Forecast - newsline.com
Number of shareholders of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
A Quick Look at Today's Ratings for Sionna Therapeutics(SION.US), With a Forecast Between $50 to $63 - Moomoo
Freedom Broker downgrades Sionna Therapeutics (SION) - MSN
Sionna Therapeutics Cut to Hold From Buy by Freedom Broker - Moomoo
SION: Phase II data for two NBD1 stabilizers in CF expected this summer, aiming for superior efficacy - TradingView
Sionna Therapeutics Price Target Maintained With a $38.00/Share by Freedom Broker - Moomoo
Finanzdaten der Sionna Therapeutics Inc-Aktie (SION)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sionna Therapeutics Inc-Aktie (SION) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thompson Peter A. | Director |
Jun 30 '26 |
Sale |
45.50 |
115,844 |
5,270,902 |
2,555,877 |
| ORBIMED ADVISORS LLC | Director |
Jun 30 '26 |
Sale |
45.50 |
115,844 |
5,270,902 |
2,555,877 |
| Thompson Peter A. | Director |
May 27 '26 |
Sale |
44.49 |
101 |
4,493 |
2,671,721 |
| ORBIMED ADVISORS LLC | Director |
May 27 '26 |
Sale |
44.49 |
101 |
4,493 |
2,671,721 |
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):